Catalog Number: 157722
Digoxin


Structure:


Molecular Formula: C₄₁H₆₄O₁₄

Molecular Weight: 780.9

CAS # 20830-75-5

Synonyms: 12b-Hydroxydigitoxin; (3b, 5b, 12b)-3-[(O-2,6-Dideoxy-b-D-ribo- hexopyranosyl- (1->4)-O-2,6- dideoxy-b-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-b-D- ribo- hexopyranosyl) oxy]-12,14- dihydroxycard-20(22)- enolide; Cordioxil

Physical Description: White powder

Description: Digoxin is a cardiotonic glycoside obtained from the leaves of Digitalis lanata Ehrhart. Increases contractile force of the cardiac muscle by inhibition of the plasma membrane Na⁺/K⁺-ATPase, leading to alterations in intracellular K⁺ and Ca²⁺ levels.^8,11 This inhibition affect may lead to magnesium depletion.¹¹ Induces apoptosis in androgen-independent human prostate cancer cell lines in vitro.⁸

Solubility: Soluble in dilute alcohol, pyridine and a mixture of chloroform and alcohol. Insoluble in ether, acetone, ethyl acetate, chloroform and water.

References:

1. Merck Index, 12th Ed., No. 3210.
2. Adrian, T., Freitag, J. and Maurer, G., "A novel high-pressure liquid extraction process for downstream processing in biotechnology: extraction of cardiac glycosides." Biotechnol. Bioeng., v. 69:5, 559-565 (2000).
3. Ball, W.J. Jr., et al., "Selection of peptidic mimics of digoxin from phage-displayed peptide libraries by anti-digoxin antibodies." J. Mol. Biol., v. 301:1, 101-115 (2000).
4. Cheng, T.O., "St. John's wort interaction with digoxin [letter]." Arch. Intern. Med., v. 160:16, 2548 (2000).
5. Dasgupta, A., Biddle, D.A., Wells, A. and Datta, P., "Positive and negative interference of the Chinese medicine Chan Su in serum digoxin measurement. Elimination of interference by using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration." Am. J. Clin. Pathol., v. 114:2, 174-179 (2000).
6. Gavaghan, B.J., "Is there still a role for digoxin in the treatment of cardiac disease?" Aust. Vet. J., v. 78:8, 528-529 (2000).
7. Leiria, T.L., Lima, G.G., Dillenburg, R.F. and Zielinsky, P., "Fetal tachyarrhythmia with 1:1 atrioventricular conduction. Adenosine infusion in the umbilical vein as a diagnostic test." Arq. Bras. Cardiol., v. 75:1, 65-68 (2000).
8. McConkey, D.J., et al., "Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells." Cancer Res., v. 60:14, 3807-3812 (2000).
9. Nagaraja, N.V., et al., "Population pharmokinetics of digoxin in Korean patients." Int. J. Clin. Pharmacol. Ther., v. 38:6, 291-297 (2000).
10. Rau, R., Hind, I.D., Wynne, R.D. and White, S.A., "Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug." Arzneimittelforschung, v. 44:3, 300-304 (1994).
11. Ravi, K.A. and Kurup, P.A., "Digoxin and membrane sodium potassium ATPase inhibition in cardiovascular disease." Indian Heart J., v. 52:3, 315-318 (2000).
12. Retzow, A., et al., "Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin." Arzneimittelforschung, v. 50:7, 591-596 (2000).
13. Roberge, R.J. and Sorensen, T., "Congestive heart failure and toxic digoxin levels: role of cholestryramine." Vet. Hum. Toxicol., v. 42:3, 172-173 (2000).
14. Tasota, F.J. and Tate, J., "Assessing digoxin levels." Nursing, v. 30:3, 24 (2000).
15. Westphal, K., et al., "Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein." Clin. Pharmacol. Ther., v. 68:1, 6-12 (2000).